Tickers: XCNQ:BUX, PINX:BMKDF
Tags: #Healthcare
Vancouver, British Columbia / TheNewswire / June 18, 2019 - BioMark Diagnostics Inc. ("BioMark") (CSE: BUX); (FSE: 20B); (OTCMKTS: BMKDF) is pleased to announce that it has arranged a voluntary debt to share settlement (the "Debt Settlement") with certain directors and officers of the Company in connection with existing indebtedness related to services provided to the Company by such directors and officers (and for which amounts had accrued as reflected in the Company's financial statements but which had not been paid).
Pursuant to the Debt Settlement, the Company will issue a total of 1,000,000 common shares (the "Debt Shares") at a deemed price of $0.15 per Debt Share in settlement of the indebtedness in aggregate amount of $150,000. No Warrants were issued in connection with the debt settlement.
Rashid Ahmed, CEO of BioMark commented, "We have chosen to increase our equity stake in BioMark as a show of confidence in our future. We are witnessing increased interest in the science and potential of metabolomics from both the medical and investment communities. As one of the leaders in metabolomics research and cancer diagnostics, we remain confident that our science and technology can have a significant impact on the lives of many people. In addition, The Company is choosing to settle the indebtedness through the issuance of Shares to preserve cash and improve the Company's balance sheet as it enters a new and exciting phase of growth."
The issuance of the Debt Shares will not result in the creation of any new control person. The Debt Shares will be subject to a four month plus 1 day hold period.
The above transaction contemplates a related party transaction as Debt Shares will be issued to directors and officers of the Company. The Company is relying on an exemption from minority shareholder approval under Multilateral Instrument 61-101 on the basis that participation by insiders does not exceed 25% of the fair market value of the Company's market capitalization.
About BioMark Diagnostics Inc.
BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.
Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website https://thecse.com/.
For further information on BioMark, please Contact:
Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
Tel. 604-370-0779
Email: info@biomarkdiagnostics.com
Forward-Looking Information:
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
The CSE has not reviewed, approved or disapproved the content of this press release.
Copyright (c) 2019 TheNewswire - All rights reserved.
